Advances in cancer immunotherapy from immune checkpoint modulation to adoptive cell transfer of tumour-infiltrating ...

Genprex (($GNPX)) announced an update on their ongoing clinical study. Study Overview: Genprex is conducting a study titled A Phase 1/2 ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

Growing use of CAR-T therapy for large B-cell lymphoma, gene delivery innovations to solid lesions, and growing investor interest are driving the cancer gene therapy industry forwardAustin, Oct. 23, ...

A new study, with help from artificial intelligence, focuses on reprogramming cancer stem cells and triggering some to ‘self-destruct’ ...

Meiragtx Holdings ((MGTX)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...

Gene therapy represents an innovative approach to treating cancer by directly modifying the genetic material within tumour cells, thereby utilising molecular mechanisms to inhibit tumour growth or ...

Biopsy specimen of a glioblastoma with prominent micovascular proliferation (formation of a mulitlayered "glomeruloid tuft", HE stain). (Jensflorian, CC BY-SA 3.0 , via Wikimedia Commons) From Philly ...

After telegraphing an investigation in November, the FDA has moved to restrict the use of bluebird bio’s gene therapy Skysona in certain patients. The FDA has updated Skysona’s indication, allowing it ...

Researchers review melanoma subtypes, focusing on therapeutic advances in metastatic ocular melanoma, including TILs, ImmTACs, and targeted therapies.

The stock makes the Nasdaq top gainers list today following news on the close yesterday. Genprex is trading at 0.7695, up ...

A one-time gene therapy using a patient’s own stem cells has effectively cured a deadly immune disorder in 95% of treated ...